Merck’s Janumet® XR — Still Just Chasing BMS/A-Z’s Kombiglyze® XR


As I first mentioned back in November 2010 (when Merck’s stock took a one-day header on the NYSE, as extended release Kombiglyze® XR won FDA approval), Merck has been — and is still — playing catch-up here. [See my Janumet® XR FDA submission day post, for background, here.]

Yesterday’s FDA approval — for a once a day version of Janumet is good news for Whitehouse Station, but it is facing an entrenched competitor, with over a year and a quarter’s lead in the market — in Kombiglyze.

Here is a bit of the Boston.com piece — do go read it all (H/t to Ed, at Pharmalot):

. . . .Drugmaker Merck & Co Inc. said Thursday it received U.S. approval for an extended-release version of its diabetes drug Janumet designed to be taken once a day, instead of twice a day.

The Food and Drug Administration approved Janumet XR to help patients with type 2 diabetes control their blood sugar levels, in combination with diet and exercise, the company said in a statement. Janumet is a combination pill that includes sitagliptin, the primary ingredient in the company’s drug Januvia, with an older diabetes drug, metformin. . . .

Again, mildly nice news — just nothing that could possibly move the needle.

Specifically, absent some very big upside surprise, Merck’s early 2012 outlook, offered on the earnings call Thursday morning all but conceded that 2012 would be a flat (dead money) year for the world’s No. 4 drugmaker. [Oh. Yes. As of year end 2011, Merck lost the No. 2 spot, as Roche lept past Pfizer, to take No. 1, and Pfizer slid to No. 2 — based on latest-projected competitor global revenue figures.]

So it goes.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s